Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2022-09-29 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于为子公司石家庄新兴药房连锁有限公司申请银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Yifeng Pharmacy Chain Co., Ltd. regarding providing a guarantee for a bank credit application by its subsidiary, Shijiazhuang Xinxing Pharmacy Chain Co., Ltd. It details the guarantee amount, the subsidiary's financial data, the necessity and reasonableness of the guarantee, and the board's opinion. The document is a formal public announcement about a financing-related guarantee and does not contain financial statements or detailed financial performance data. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided for bank credit.
2022-09-29 Chinese
独立董事关于公司第四届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion related to the 19th meeting of the 4th board of directors of the company. It discusses the review and approval of related party transactions and guarantees for subsidiaries, referencing compliance with company rules and regulatory guidelines. The content is a formal opinion or statement from independent directors rather than a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy solicitation. The document is a governance-related statement about board meeting matters and compliance with regulations. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board-related opinions, not a full report or announcement of a report publication.
2022-09-29 Chinese
益丰药房关于参加2022年度湖南辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event organized by regulatory bodies and associations. It details the event's date, time, platform, and encourages investor participation. There is no financial data, no report attached or published, and no mention of a formal report or filing. The document is a regulatory announcement related to investor relations and communication, not a financial report or meeting material. Given the short length (790 characters) and the nature of the content, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-09-22 Chinese
益丰药房2022年限制性股票激励计划首次授予激励对象名单（调整后）
Board/Management Information Classification · 95% confidence The document is a detailed list of individuals receiving restricted stock awards under a 2022 restricted stock incentive plan, including their positions and the number of shares granted. It focuses on core management and key technical personnel, listing names and roles extensively. There is no indication of financial statements, audit opinions, earnings data, or regulatory certifications. The content is about management incentives and stock awards, which aligns with disclosures related to executive compensation or management information. However, it is not a remuneration report detailing compensation amounts or policies, but rather a specific announcement of stock incentive allocations to management. This fits best under Board/Management Information (MANG), which includes announcements related to management changes or incentives. The document length (5722 characters) and detailed content support it being a substantive announcement rather than a brief notice or regulatory filing. Therefore, the classification is MANG with high confidence.
2022-09-16 Chinese
益丰药房独立董事关于第四届董事会第十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the company's fourth board meeting, specifically regarding adjustments and grant of restricted stock incentive plans in 2022. It references compliance with securities laws, company law, stock incentive management measures, and stock exchange listing rules. The content focuses on governance and approval of stock incentive plans rather than financial results or audit findings. The document length is short (1321 characters) and it is a formal opinion related to board decisions on stock incentives, which fits best under Board/Management Information (MANG) as it relates to management and board-level decisions and disclosures about stock incentive plans.
2022-09-16 Chinese
益丰药房2022年限制性股票激励计划（修订版）
Remuneration Information Classification · 95% confidence The document is titled "益丰药房 2022 年限制性股票激励计划" which translates to "Yifeng Pharmacy 2022 Restricted Stock Incentive Plan." It details the company's stock incentive plan for 2022, including the number of shares to be granted, the eligibility criteria for recipients, the grant price, vesting and lock-up periods, performance conditions, accounting treatment, and legal compliance references. The document is comprehensive and lengthy (15,000 characters), containing detailed terms and conditions of the stock incentive plan rather than a brief announcement or summary. It is not a financial report, earnings release, or regulatory filing but a detailed plan related to executive remuneration and stock incentives. According to the filing definitions, a report detailing compensation for top executives and directors, including stock incentive plans, falls under "Remuneration Information (DEF 14A)". Therefore, this document should be classified as DEF 14A with high confidence.
2022-09-16 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.